Replies to post #191636 on Biotech Values

[genisi]

Why is BXLT’s gene-therapy candidate for hemophilia A about two years behind its gene-therapy candidate for hemophilia B?

I think the large size of human FVIII cDNA (much larger than that of factor IX) was a challenge for delivery by the viral vector (few more problems I can think of but not as challenging), and it took time to overcome this problem.